Gregory Covino - Biogen Insider

Chief Accounting Officer, VP of Fin. and Controller

Mr. Gregory F. Covino is Chief Accounting Officer, Vice President Finance of Biogen Inc., since April 2012
Age: 49  VP Since 2012      
617 679-2000  www.biogenidec.com
Gregory Covino EducationCovino has served as our Vice President, Finance and Chief Accounting Officer since April 2012. Prior to that, Mr. Covino served at Boston Scientific Corporationrationration, a medical device company, as Vice President, Corporationrationrate Analysis and Control since March 2010, having responsibility for the company internal audit function, and as Vice President, Finance, International from February 2008 to March 2010, having responsibility for the financial activities of the company international division. Prior to that, Mr. Covino held several finance positions at Hubbell Incorporated, an electrical products company, including Vice President, Chief Accounting Officer and Controller from 2002 to January 2008, Interim Chief Financial Officer from 2004 to 2005, and Director, Corporationrationrate Accounting from 1999 to 2002. He received his B.S. in Business Administration from Bryant University.

Gregory Covino Latest Insider Trades

Management Efficiency

The company has return on total asset (ROA) of 0.16 % which means that it generated profit of $0.16 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 11.3 % meaning that it created $11.3 on every $100 dollars invested by stockholders.
The company currently holds 6.52 B in liabilities with Debt to Equity (D/E) ratio of 0.54 which is about average as compared to similar companies. Biogen Inc has Current Ratio of 3.18 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Found 4 records

VP Since

John ThomasAbbott Laboratories
N/A
Julie YankovichEndo International plc
N/A
James StarkBioRad Laboratories Inc
N/A
Daniel RudioEndo International plc
N/A

Entity Summary

Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurodegenerative diseases, hematologic conditions, and autoimmune disorders. Biogen Inc (BIIB) is traded on NASDAQ in USA. It is located in MASSACHUSETTS, U.S.A and employs 7,350 people. Biogen is listed under Pharmaceutical Products category by Fama And French industry classification and specializes in Healthcare with concentration in Pharmaceuticals And Biosciences.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Biogen Inc to your portfolio

Top Management

Biogen Inc Leadership Team
Richard Mulligan, Director
Paul McKenzie, President, Ph.D
Michel Vounatsos, President, MBA
George Scangos, CEO, Ph.D
Alfred Sandrock, President, Ph.D
Stuart Kingsley, EVP
Spyros ArtavanisTsakonas, President, Ph.D
Alexander Denner, Director
Douglas Williams, EVP
Eric Rowinsky, Director, Ph.D
Adriana Karaboutis, EVP
Paul MBA, CFO
Kenneth Pietro, President
Adam Koppel, President, MBA
Stephen Sherwin, Director, Ph.D
Caroline Dorsa, Director
Michael Ehlers, President, Ph.D
Susan Alexander, President
Paul Clancy, CFO, MBA
Steven Holtzman, President
Nancy Leaming, Director
Lynn Schenk, Director
Brian Posner, Director
Gregory Covino, VP
Tony Kingsley, President, MBA
Stelios Papadopoulos, Chairman, Ph.D
John Cox, EVP, MBA
Adriana MS, EVP
Robert Pangia, Director
Matt Griffiths, President

Stock Performance

Biogen Performance Indicators